Karyopharm Therapeutics (KPTI) Raised to Hold at ValuEngine

ValuEngine upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a sell rating to a hold rating in a research note released on Monday morning, ValuEngine reports.

KPTI has been the topic of several other research reports. Zacks Investment Research downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a report on Saturday, March 2nd. BidaskClub raised Karyopharm Therapeutics from a strong sell rating to a sell rating in a report on Wednesday, March 20th. HC Wainwright reissued a buy rating on shares of Karyopharm Therapeutics in a report on Wednesday, February 27th. JPMorgan Chase & Co. downgraded Karyopharm Therapeutics from an overweight rating to a neutral rating and cut their price objective for the company from $21.00 to $7.00 in a report on Friday, March 1st. Finally, Wedbush cut their price objective on Karyopharm Therapeutics from $19.00 to $14.00 and set an outperform rating on the stock in a report on Monday, February 25th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. Karyopharm Therapeutics currently has an average rating of Hold and a consensus target price of $17.75.

Shares of KPTI opened at $5.79 on Monday. Karyopharm Therapeutics has a 52-week low of $3.92 and a 52-week high of $21.71. The company has a current ratio of 6.19, a quick ratio of 6.19 and a debt-to-equity ratio of 0.98.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.75 million. As a group, equities research analysts predict that Karyopharm Therapeutics will post -3.77 earnings per share for the current year.

In related news, major shareholder Ltd Chione sold 1,481,643 shares of the firm’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $4.81, for a total transaction of $7,126,702.83. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 13.26% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in KPTI. Bank of New York Mellon Corp lifted its holdings in Karyopharm Therapeutics by 2.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 218,594 shares of the company’s stock worth $3,723,000 after buying an additional 4,576 shares during the period. AQR Capital Management LLC lifted its holdings in Karyopharm Therapeutics by 60.6% during the 3rd quarter. AQR Capital Management LLC now owns 30,767 shares of the company’s stock worth $524,000 after buying an additional 11,614 shares during the period. Federated Investors Inc. PA lifted its holdings in Karyopharm Therapeutics by 11,995.4% during the 3rd quarter. Federated Investors Inc. PA now owns 295,854 shares of the company’s stock worth $5,038,000 after buying an additional 293,408 shares during the period. IFP Advisors Inc lifted its holdings in Karyopharm Therapeutics by 197.4% during the 4th quarter. IFP Advisors Inc now owns 5,650 shares of the company’s stock worth $52,000 after buying an additional 3,750 shares during the period. Finally, Emerald Advisers LLC lifted its holdings in Karyopharm Therapeutics by 109.8% during the 4th quarter. Emerald Advisers LLC now owns 1,456,473 shares of the company’s stock worth $13,647,000 after buying an additional 762,405 shares during the period. 87.72% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

See Also: Outstanding Shares, Buying and Selling Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.